Please use this identifier to cite or link to this item:
Title: Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas
Authors: Yao, Li
Schiavi, Francesca
Cascon, Alberto
Qin, Yuejuan
Inglada-Perez, Lucia
King, Elizabeth E.
Toledo, Rodrigo A.
Ercolino, Tonino
Rapizzi, Elena
Ricketts, Christopher J.
Mori, Luigi
Giacche, Mara
Mendola, Antonella
Taschin, Elisa
Boaretto, Francesca
Loli, Paola
Iacobone, Maurizio
Rossi, Gian-Paolo
Biondi, Bernadette
Lima-Junior, Jose Viana [UNIFESP]
Kater, Claudio E. [UNIFESP]
Bex, Marie
Vikkula, Miikka
Grossman, Ashley B.
Gruber, Stephen B.
Barontini, Marta
Persu, Alexandre
Castellano, Maurizio
Toledo, Sergio P. A.
Maher, Eamonn R.
Mannelli, Massimo
Opocher, Giuseppe
Robledo, Mercedes
Dahia, Patricia L. M.
Univ Texas Hlth Sci Ctr San Antonio
Univ Padua
Spanish Natl Canc Res Ctr
Inst Salud Carlos III
Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Univ Florence
Ist Toscano Tumori
Univ Birmingham
Univ Brescia
Catholic Univ Louvain
Osped Niguarda Ca Granda
Univ Naples Federico 2
Katholieke Univ Leuven Hosp
St Bartholomews Hosp
Univ Michigan
Hosp Ninos Dr Ricardo Gutierrez
Issue Date: 15-Dec-2010
Publisher: Amer Medical Assoc
Citation: Jama-Journal of the American Medical Association. Chicago: Amer Medical Assoc, v. 304, n. 23, p. 2611-2619, 2010.
Abstract: Context Pheochromocytomas and paragangliomas are genetically heterogeneous neural crest-derived neoplasms. We recently identified germline mutations of the novel transmembrane-encoding gene FP/TMEM127 in familial and sporadic pheochromocytomas consistent with a tumor suppressor effect.Objectives To examine the prevalence and spectrum of FP/TMEM127 mutations in pheochromocytomas and paragangliomas and to test the effect of mutations in vitro.Design, Setting, and Participants We sequenced the FP/TMEM127 gene in 990 individuals with pheochromocytomas and/or paragangliomas, including 898 previously unreported cases without mutations in other susceptibility genes from 8 independent worldwide referral centers between January 2009 and June 2010. A multiplex polymerase chain reaction-based method was developed to screen for large gene deletions in 545 of these samples. Confocal microscopy of 5 transfected mutant proteins was used to determine their subcellular localization.Main Outcome Measures the frequency and type of FP/TMEM127 mutation or deletion was assessed and correlated with clinical variables; the subcellular localization of 5 overexpressed mutants was compared with wild-type FP/TMEM127 protein.Results We identified 19 potentially pathogenic FP/TMEM127 germline mutations in 20 independent families, but no large deletions were detected. All mutation carriers had adrenal tumors, including 7 bilateral (P=2.7 x 10(-4)) and/or with familial disease (5 of 20 samples; P=.005). the median age at disease onset in the FP/TMEM127 mutation group was similar to that of patients without a mutation (41.5 vs 45 years, respectively; P=.54). the most common presentation was that of a single benign adrenal tumor in patients older than 40 years. Malignancy was seen in 1 mutation carrier (5%). Expression of 5 novel FP/TMEM127 mutations in cell lines revealed diffuse localization of the mutant proteins in contrast with the discrete multiorganelle distribution of wild-type TMEM127.Conclusions Germline mutations of FP/TMEM127 were associated with pheochromocytoma but not paraganglioma and occured in an age group frequently excluded from genetic screening algorithms. Disease-associated mutations disrupt intracellular distribution of the FP/TMEM127 protein. JAMA. 2010;304(23):2611-2619
ISSN: 0098-7484
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.